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Cladosporin is an antimalarial drug that acts as an ATP-mimetic to selectively inhibit Plasmodium lysyl-tRNA
synthetase. Using multiple crystal structures, Fang et al. (2015) reveal in this issue of Chemistry & Biology the
fascinating mechanism responsible for cladosporin selectivity.For everyone working on developing
drugs to treat infectious diseases, it is
clear that the big question is when the
resistance to a given drug will emerge.
If humankind is to win this tug-of-war,
the continuous development of novel
antimicrobial targets and inhibitors is
essential. Historically, bacterial cell wall
synthesis, DNA and RNA synthesis, and
gene translation have been major targets
of very successful classes of drugs
such as beta-lactams, glycopeptides, or
tetracyclines. In this regard, the amino-
acyl-tRNA synthetases (ARS) represent
a heavily studied but relatively unused
family of targets. These enzymes cata-
lyze the essential attachment of amino
acids to their cognate transfer RNAs
(tRNA), which are then used during
gene translation. These enzymes areFigure 1. Aminoacyl-tRNA Synthetase Inhibitors Currently Serving
as Scaffolds for the Development of New Antimalarials
Each ARS has been classified into its two classes and 3 subclasses based on
its fold and tRNA recognition mode (Ribas de Pouplana and Schimmel, 2001).ancient and universal; there-
fore, a major requisite for
any anti-infective drug target-
ing ARS is high selectivity.
Currently, only two ARS in-
hibitors are on the market:
the antibiotic mupirocin, used
for the topical treatment of
methicillin-resistant Staphylo-
coccus aureus, and the ben-
zoxaborole AN2690, used for
the treatment of onychomyco-
sis. These drugs prove that
selective and efficacious inhi-
bition of ARS is a feasible
approach for anti-infective
development.
In the last few years, the
interest in the use of ARS in-
hibitors as antimalarial drug
targets has surged (Istvan
et al., 2011; Keller et al.,2012; Hoen et al., 2013; Novoa et al.,
2014; Pham et al., 2014). The efforts to
develop antimalarial drugs targeting
ARS have mainly consisted of classical
approaches such as the use of libraries
of analogs based on aminoacyl-adeny-
late intermediates or the modification of
natural products such as mupirocin or
borrelidin (Figure 1). However, three
years ago, a discovery reported by the
Winzeler lab opened a new and exciting
avenue in this area.
In 2012, Hoepfner and colleagues re-
ported that cladosporin, a previously
identified inhibitor of Plasmodium, was in
fact targeting the lysyl-tRNA synthetase
(LysRS) of the parasite (Hoepfner et al.,
2012). Cladosporin (CP) had been previ-
ously identified through high-throughput
screens as a potent, nanomolar-rangeChemistry & Biology 22, June 18, 2015antimalarial, active in both the blood and
the liver stages of this infection (Plouffe
et al., 2008). This finding was important
because it provided a novel chemical
scaffold targeting an ARS that could
potentially be used against a broad range
of pathogens.
New scaffolds raise new questions,
however, and chief among them were
the reasons for cladosporin’s remarkable
activity and selectivity. Hoepfner and col-
leagues first attempted to answer these
points using in silico approaches based
on homology modeling and docking.
Based on these analyses, it was sug-
gested that cladosporin was binding to
the ATP binding pocket of LysRS (Hoepf-
ner et al., 2012). But this conclusion raised
a new question: why is cladosporin selec-
tive toward LysRS and does not inhibitª2015 Elseother ARS, which also have a
very similar ATP-binding site?
In this issue, Fang et al.
(2015) report a series of crys-
tal structures of cladosporin-
bound human and plasmo-
dial LysRS (HsLysRS-CP and
PfLysRS-CP, respectively),
including mutants and combi-
nations of ligands. Although
cladosporin is an ATP
mimetic, only the isocoumarin
moiety of CP binds LysRS
through interactions shared
with ATP. These interactions
involve residues that are
conserved in several amino-
acyl-tRNA synthetases and
across many species and
cannot be the basis for CP’s
selectivity. The reason why
cladosporin is specific forvier Ltd All rights reserved 685
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PreviewsLysRS is found in the interactions of the
methyltetrahydro-pyran moiety of the
drug with three residues out of the ATP
binding pocket, which are idiosyncratic
to LysRS.
Interestingly, this is not the end of
this story. The three key residues dif-
ferentiating LysRS from other ARS are
conserved across eukaryotic LysRS, so
they cannot, by themselves, explain the
high species selectivity displayed by CP.
Indeed, the binding mode of cladosporin
to both HsLysRS and PfLysRS is nearly
identical in the structures solved by the
Guo lab (Fang et al., 2015). So what are
the bases for CP’s selectivity toward the
plasmodial enzyme?
The answer to this riddle was provided
by solving an additional structure of
CP bound to PfLysRS without the
amino acid lysine, which demonstrated
a strong cooperativity in the binding of
CP and lysine. Binding of lysine to
PfLysRS induces a series of conforma-
tional changes in the active site of the
enzyme that further favor the binding of
cladosporin and stabilize the complex
PfLysRS-lys-CP. This cooperativity is
not seen in the human enzyme, which is
not stabilized by lysine and CP, and this
lack of cooperativity explains the selec-
tive inhibition of the plasmodial enzyme
by cladosporin.686 Chemistry & Biology 22, June 18, 2015 ªA few years ago, the development of
new leucyl-tRNA synthetase (LeuRS) in-
hibitors based on a benzoxaborole scaf-
fold brought to light an unexpected
inhibitory mechanism. The crystal struc-
ture of LeuRS cocrystallized with
AN2690 revealed that this compound
formed a covalent bond with the terminal
adenosine (A76) of tRNALeu in the editing
active site of LeuRS, thus trapping the
substrate and impeding the aminoacyla-
tion reaction (Rock et al., 2007). Just as
unexpectedly, the work of Fang et al.
(2015) reveals a new molecular mecha-
nism for the specific inhibition of LysRS
by cladosporin and provides a new
approach for the design of isocoumarin-
based compounds to selectively target
ARS from a wide range of pathogenic
species.
Although cladosporin possesses poor
oral bioavailability (Hoepfner et al.,
2012), the understanding of its mecha-
nism of action should now allow the
development of programs to design iso-
coumarin-based scaffolds with increased
oral bioavailability while maintaining CP’s
activity and selectivity.ACKNOWLEDGMENTS
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